Testicular Germ Cell Tumor disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

TGCT MCID: TST021 MIFTS: 58	Testicular Germ Cell Tumor (TGCT) Categories: Cancer diseases, Fetal diseases, Genetic diseases, Rare diseases, Reproductive diseases, Skin diseases	Data Licensing For inquiries, contact: [email protected]
Genes Variations Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Testicular Germ Cell Tumor

MalaCards integrated aliases for Testicular Germ Cell Tumor:

Name: Testicular Germ Cell Tumor ⁵⁷ ⁷³ ¹⁶ ⁷¹

Male Germ Cell Tumor ⁵⁷ ⁷³ ⁷¹

Testicular Teratoma ⁵⁸ ⁵³ ¹⁶

Testicular Non-Seminomatous Germ Cell Tumor ¹⁶ ⁷¹

Spermatocytic Seminoma, Somatic ⁵⁷ ⁵

Male Germ Cell Tumor, Somatic ⁵⁷ ⁵

Embryonal Cell Carcinoma ⁷³ ⁷¹

Spermatocytic Seminoma ⁷³ ⁷¹

Seminoma ⁷³ ⁷¹

Tgct ⁵⁷ ⁷³

Mgct ⁵⁷ ⁷³

Malignant Testicular Non-Seminomatous Germ Cell Tumor ⁷¹

Testicular Non-Dysgerminomatous Germ Cell Tumor ⁵⁸

Non-Dysgerminomatous Germ Cell Tumor of Testis ⁵⁸

Testicular Non Seminomatous Germ Cell Tumor ⁵⁸

Non-Seminomatous Germ Cell Tumor of Testis ⁵⁸

Nonseminomatous Germ Cell Tumors ⁷³

Nonseminomatous Germ Cell Tumor ⁷¹

Germ Cell Tumors, Somatic ⁵⁷

Testicular Tumor, Somatic ⁵⁷

Germ Cell Tumor, Somatic ⁵

Embryonal Carcinoma Cell ¹⁶

Endodermal Sinus Tumor ⁷³

Teratoma of the Testis ⁵⁸

Teratoma Testicular ⁷³

Teratoma of Testis ⁷¹

Yolk Sac Tumor ⁷¹

Characteristics:

Inheritance:

Somatic mutation ⁵⁷

Prevelance:

Non-Seminomatous Germ Cell Tumor of Testis: 1-9/100000 (Europe) 1-5/10000 (Europe) ⁵⁸

Testicular Teratoma: <1/1000000 (Europe) ⁵⁸

Age Of Onset:

Non-Seminomatous Germ Cell Tumor of Testis: Adult ⁵⁸

OMIM®:

⁵⁷ (Updated 08-Dec-2022)

Miscellaneous:
two subtypes - seminoma and nonseminoma
occasionally germ cell tumor arise from extra gonadal site (e.g., mediastinum, retroperitoneum, pineal gland)
most common cancer in men aged 15-40 years
highest incidence in men of european descent
risk factors for development of tgct - family history, cryptorchidism , testicular feminization , klinefelter syndrome, previous tgct, gonadal dysgenesis

Classifications:

MalaCards categories:
Global: Genetic diseases Cancer diseases Rare diseases Fetal diseases
Anatomical: Skin diseases Reproductive diseases

See all MalaCards categories (disease lists)

ICD10: ³²

Neoplasms

Malignant neoplasms of male genital organs

Malignant neoplasm of testis

Malignant neoplasm: Descended testis

Malignant neoplasm: Testis, unspecified

Orphanet: ⁵⁸

Rare urogenital diseases

External Ids:

OMIM® ⁵⁷ 273300

MeSH ⁴³ D013736 D018239

ICD10 via Orphanet ³² C62.1 C62.9

UMLS via Orphanet ⁷² C0238451

Orphanet ⁵⁸ ORPHA363483 ORPHA363494

MedGen ⁴⁰ C0014145 C0036631 C0238451 more

SNOMED-CT via HPO ⁶⁹ 188188009 425558002 44769000 more

EFO ¹⁶ EFO_0004987 EFO_1000566 EFO_1000570 more

UMLS ⁷¹ C0014145 C0036631 C0238451 more

Sources

Summaries for Testicular Germ Cell Tumor

OMIM®: ⁵⁷ Testicular germ cell tumors (TGCTs) affect 1 in 500 men and are the most common cancer in males aged 15 to 40 in western European populations. The incidence of TGCT rose dramatically during the 20th century. Known risk factors for TGCT include a history of undescended testis (UDT), testicular dysgenesis, infertility, previously diagnosed TGCT, and a family history of the disease. Brothers of men with TGCT have an 8- to 10-fold risk of developing TGCT, whereas the relative risk to fathers and sons is 4-fold. This familial relative risk is much higher than that for most other types of cancer (summary by Rapley et al., 2000). (273300) (Updated 08-Dec-2022)

MalaCards based summary: Testicular Germ Cell Tumor, also known as male germ cell tumor, is related to testicular spermatocytic seminoma and spermatocytoma. An important gene associated with Testicular Germ Cell Tumor is FGFR3 (Fibroblast Growth Factor Receptor 3), and among its related pathways/superpathways are p70S6K Signaling and PI3K-Akt signaling pathway. The drugs Granisetron and Levofloxacin have been mentioned in the context of this disorder. Affiliated tissues include testis, pineal and lymph node, and related phenotypes are azoospermia and elevated alpha-fetoprotein

Orphanet ⁵⁸ Testicular teratoma: A rare neoplastic disease characterized by the presence of a testicular tumor composed of several, well-differentiated or immature, tissues derived from one or more of the 3 germinal layers. Patients typically present unilateral (occasionally bilateral) painless testicular swelling or a palpable testicular nodule/mass.

Non-seminomatous germ cell tumor of testis: A form of testicular germ cell tumor occurring in the third decade of life with a usually painless unilateral mass in the scrotum or, in some cases, with gynaecomastia and/or back and flack pain. The clinical course is more aggressive than testicular seminomatous germ cell tumors with rapid involvement of blood vessels and a poorer prognosis. Histologically, the tumour can be either undifferentiated (embryonal carcinoma), differentiated (teratoma, yolk sac tumor, choriocarcinoma), or can consist of a mixture of seminomatous and nonseminomatous components.

UniProtKB/Swiss-Prot: ⁷³ A common malignancy in males representing 95% of all testicular neoplasms. TGCTs have various pathologic subtypes including: unclassified intratubular germ cell neoplasia, seminoma (including cases with syncytiotrophoblastic cells), spermatocytic seminoma, embryonal carcinoma, yolk sac tumor, choriocarcinoma, and teratoma.

Sources

Related Diseases for Testicular Germ Cell Tumor

Diseases in the Testicular Germ Cell Tumor family:

Testicular Germ Cell Tumor 1

Diseases related to Testicular Germ Cell Tumor via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 803)

#	Related Disease	Score	Top Affiliating Genes
1	testicular spermatocytic seminoma	32.2	HRAS FGFR3
2	spermatocytoma	32.0	MIR371A LRRC56 KIT HRAS FGFR3
3	germ cell tumor	31.9	TGCT1 STK11 STK10 KIT FGFR3
4	testicular germ cell cancer	31.1	STK11 MIR373 MIR372 MIR371A MIR367 KITLG
5	endodermal sinus tumor	31.0	MIR373 MIR371A KIT
6	thymoma	30.5	LRRC56 KIT HRAS
7	testicular cancer	30.5	STK11 MIR373 MIR372 MIR371A KITLG KIT
8	neurofibromatosis, type i	30.2	KITLG KIT HRAS
9	germ cell cancer	30.2	MIR373 MIR371A MIR302D KITLG KIT
10	childhood germ cell cancer	30.2	MIR371A KITLG
11	ovarian germ cell cancer	30.2	MIR371A KIT
12	dysgerminoma	30.2	MIR371A KITLG KIT
13	gastrointestinal stromal tumor	30.1	KITLG KIT HRAS FGFR3
14	malignant teratoma	30.1	MIR371A KIT
15	mast-cell sarcoma	29.9	KITLG KIT
16	lymphatic system disease	29.9	MIR373 MIR200C MIR145 MIR140
17	testicular disease	29.7	MIR372 MIR371A KITLG KIT
18	brain germinoma	29.7	MIR373 MIR371A KITLG KIT
19	dysgerminoma of ovary	29.6	MIR371A KITLG KIT
20	myeloproliferative neoplasm	29.6	KITLG KIT HRAS FGFR3
21	renal cell carcinoma, papillary, 1	29.6	LRRC56 KIT HRAS FGFR3
22	rectum cancer	29.5	MIR145 MIR140 HRAS
23	suppression of tumorigenicity 12	29.5	MIR145 LRRC56 HRAS
24	gliosarcoma	29.5	LRRC56 HRAS FGFR3
25	thyroid gland anaplastic carcinoma	29.4	MIR145 KIT HRAS
26	noonan syndrome 1	29.4	LRRC56 HRAS FGFR3 BCL10
27	head and neck cancer	29.2	MIR373 MIR145 MIR140 HRAS
28	leukemia, chronic lymphocytic	29.1	MIR373 MIR145 MIR140 LRRC56 KIT HRAS
29	malignant astrocytoma	29.0	MIR373 MIR200C MIR145 MIR140
30	melanoma	29.0	STK11 MIR302D MIR200C MIR140 LRRC56 KITLG
31	hematologic cancer	28.9	MIR200C MIR145 MIR140 KITLG KIT HRAS
32	lung cancer susceptibility 3	28.7	STK11 MIR200C MIR145 MIR140 LRRC56 HRAS
33	lymphoma, non-hodgkin, familial	28.6	MIR373 MIR200C MIR145 MIR140 KITLG BCL10
34	leukemia, acute myeloid	28.1	MIR372 MIR367 MIR302D MIR145 MIR140 LRRC56
35	lung cancer	27.4	STK11 MIR373 MIR372 MIR367 MIR200C MIR145
36	nervous system disease	27.0	MIR373 MIR371A MIR367 MIR302D MIR200C MIR145
37	testicular germ cell tumor 1	11.8
38	childhood endodermal sinus tumor	11.7
39	childhood testicular germ cell tumor	11.7
40	ovarian endodermal sinus tumor	11.6
41	testicular yolk sac tumor	11.6
42	adult endodermal sinus tumor	11.6
43	childhood ovarian endodermal sinus tumor	11.6
44	yolk sac tumor of central nervous system	11.5
45	pigmented villonodular synovitis	11.5
46	childhood cns embryonal cell carcinoma	11.5
47	testicular seminoma	11.5
48	central nervous system endodermal sinus tumor	11.4
49	testis seminoma	11.4
50	testicular germ cell tumor non-seminomatous	11.3

Graphical network of the top 20 diseases related to Testicular Germ Cell Tumor:

Sources

Symptoms & Phenotypes for Testicular Germ Cell Tumor

Human phenotypes related to Testicular Germ Cell Tumor:

³⁰

#	Description	HPO Source Accession
1	azoospermia ³⁰	HP:0000027
2	elevated alpha-fetoprotein ³⁰	HP:0006254
3	teratoma ³⁰	HP:0009792
4	choriocarcinoma ³⁰	HP:0100768
5	embryonal neoplasm ³⁰	HP:0002898

Symptoms via clinical synopsis from OMIM®:

⁵⁷ (Updated 08-Dec-2022)

Genitourinary Internal Genitalia Male:
painless testicular mass

Laboratory Abnormalities:
isochromosome 12p (i(12p))
elevated hcg (choriocarcinoma)
elevated afp (endodermal sinus tumor)
elevated hcg or afp or both (embryonal carcinoma)
azoospermia/oligospermia (present at diagnosis)

Neoplasia:
male germ cell tumors (gct), 2 subtypes -
seminoma
nonseminoma (embryonal carcinoma, teratoma, choriocarcinoma, endodermal sinus tumor)

Clinical features from OMIM®:

273300 (Updated 08-Dec-2022)

Sources

Drugs & Therapeutics for Testicular Germ Cell Tumor

Drugs for Testicular Germ Cell Tumor (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 194)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Granisetron

Approved, Investigational

Phase 3

109889-09-0

3510 5284566

Levofloxacin

Approved, Investigational

Phase 3

100986-85-4

149096

Ofloxacin

Approved

Phase 3

82419-36-1

4583

Midazolam

Approved, Illicit

Phase 3

59467-70-8

4192

Selenium

Approved, Investigational, Vet_approved

Phase 3

7783-07-5, 7782-49-2

533

Tocopherol

Approved, Investigational

Phase 3

1406-66-2

Etoposide

Approved

Phase 3

33419-42-0

36462

Carboplatin

Approved

Phase 3

41575-94-4

10339178 38904

Lenograstim

Approved, Investigational

Phase 3

135968-09-1

Coenzyme M

Approved, Investigational

Phase 3

3375-50-6

598 23662354

Diphenhydramine

Approved, Investigational

Phase 3

147-24-0, 58-73-1

3100

Promethazine

Approved, Investigational

Phase 3

60-87-7

4927

Picropodophyllin

Approved, Investigational

Phase 3

518-28-5, 477-47-4

10607 72435

Bleomycin

Approved, Investigational

Phase 3

9041-93-4, 11056-06-7

5360373

Oxaliplatin

Approved, Investigational

Phase 3

61825-94-3

43805 11947679 6857599

Cisplatin

Approved

Phase 3

15663-27-1

2767 5702198 441203

Paclitaxel

Approved, Vet_approved

Phase 3

33069-62-4

36314

Ifosfamide

Approved

Phase 3

3778-73-2

3690

Vinblastine

Approved

Phase 3

865-21-4

241903 13342

Estradiol

Approved, Investigational, Vet_approved

Phase 3

50-28-2

5757

Ethinylestradiol

Approved

Phase 3

57-63-6

5991

Polyestradiol phosphate

Approved

Phase 3

28014-46-2

Norgestimate

Approved, Investigational

Phase 3

35189-28-7

6540478

Moxifloxacin

Approved, Investigational

Phase 3

186826-86-8, 354812-41-2, 151096-09-2

152946

DL-alpha-Tocopherol

Approved, Experimental, Investigational, Nutraceutical, Vet_approved

Phase 3

59-02-9, 10191-41-0

2116 14985

Ascorbic acid

Approved, Nutraceutical

Phase 3

50-81-7

54676860 54670067 5785

Aspartic acid

Approved, Nutraceutical

Phase 3

56-84-8

5960

Racemethionine

Approved, Experimental, Investigational, Nutraceutical

Phase 3

59-51-8, 63-68-3, 348-67-4

6137

Tocotrienol

Investigational

Phase 3

6829-55-6

9929901

Palifosfamide

Investigational

Phase 3

31645-39-3

100427

Neurotransmitter Agents

Phase 3

Liver Extracts

Phase 3

Cytochrome P-450 Enzyme Inhibitors

Phase 3

Vitamins

Phase 3

Calcium, Dietary

Phase 3

N-Methylaspartate

Phase 3

Antioxidants

Phase 3

Tocotrienols

Phase 3

Tocopherols

Phase 3

Etoposide phosphate

Phase 3

16760419

Antibiotics, Antitubercular

Phase 3

Dermatologic Agents

Phase 3

Adjuvants, Immunologic

Phase 3

Histamine H2 Antagonists

Phase 3

Keratolytic Agents

Phase 3

Anti-Bacterial Agents

Phase 3

Anti-Infective Agents

Phase 3

Albumin-Bound Paclitaxel

Phase 3

Antimitotic Agents

Phase 3

Tubulin Modulators

Phase 3

Interventional clinical trials:

(show top 50) (show all 135)

#	Name	Status	NCT ID	Phase	Drugs
1	Trial of Imaging and Schedule in Seminoma Testis	Unknown status	NCT00589537	Phase 3
2	Randomized Phase II/III Study of Taxol/Paclitaxel-BEP Versus BEP in Patients With Intermediate Prognosis Germ Cell Cancer	Unknown status	NCT00003643	Phase 2, Phase 3	cisplatin;etoposide;paclitaxel
3	Randomized Double-Blind Controlled Phase III Trial of Hyperbaric Oxygen Therapy in Patients Suffering Long-Term Adverse Effects of Radiotherapy for Pelvic Cancer (HOT II)	Unknown status	NCT01087268	Phase 3
4	A Study to Investigate the Efficacy and Tolerability of Two Dose Levels of Lerisetron Compared With Granisetron in Patients Receiving Radiotherapy for Stage I Seminoma	Unknown status	NCT00004219	Phase 3	granisetron hydrochloride;lerisetron
5	A Single Group Trial Evaluating One Cycle of Adjuvant BEP Chemotherapy in High Risk, Stage 1 Non-seminomatous Germ Cell Tumours of the Testis (NSGCTT)	Unknown status	NCT01726374	Phase 3	BEP(500)
6	A Phase III Study Of Reduced Therapy In The Treatment Of Children With Low And Intermediate Risk Extracranial Germ Cell Tumors	Completed	NCT00053352	Phase 3	cisplatin;etoposide
7	A Randomized, Prospective Double-Blind, Placebo-Controlled Trial of Prophylactic Oral Levofloxacin Following Chemotherapy for Lymphoma and Solid Tumors	Completed	NCT00005590	Phase 3	levofloxacin
8	INTERNATIONAL RANDOMIZED STUDY FOR THE SALVAGE TREATMENT OF GERM CELL TUMOURS	Completed	NCT00002566	Phase 3	carboplatin;cisplatin;cyclophosphamide;etoposide;ifosfamide;vinblastine sulfate
9	RANDOMIZED MULTIINSTITUTIONAL PHASE III TRIAL OF BEP AND HIGH DOSE CHEMOTHERAPY VERSUS BEP ALONE IN PREVIOUSLY UNTREATED PATIENTS WITH POOR RISK GERM CELL TUMORS	Completed	NCT00002596	Phase 3	carboplatin;cisplatin;cyclophosphamide;etoposide
10	A Randomized Phase III Toxicity Study of Day 2, 3, 8, 15 Short (30 Minute) Versus Day 1, 2, 3 Long (72 Hours) Infusion Bleomycin for Patients With IGCCCG Good Prognosis Germ Cell Tumors, TE3	Completed	NCT00324298	Phase 3	cisplatin;etoposide
11	A Randomized Phase III Study of Sequential High-Dose Cisplatinum/Etoposide/Ifosfamide Plus Stem Cell Support Versus BEP in Patients With Poor Prognosis Germ Cell Cancer	Completed	NCT00003941	Phase 3	cisplatin;etoposide;ifosfamide
12	Carboplatin in the Adjuvant Treatment of Stage I Seminoma: A Radomized Comparison of Single Agent Carboplatin With Radiotherapy in the Adjuvant Treatment of Stage I Seminoma of the Testis, Following Orchidectomy	Completed	NCT00003014	Phase 3	carboplatin
13	A Randomized Double Blinded Trial of Topical Caphosol to Prevent Oral Mucositis in Children Undergoing Hematopoietic Stem Cell Transplantation	Completed	NCT01305200	Phase 3	supersaturated calcium phosphate rinse
14	Double Blind Randomised Controlled Trial to Investigate the Efficacy of ANTOX (Vers) 1.2 and MGCT (Magnesiocard) for the Treatment of Hereditary Pancreatitis and Idiopathic Chronic Pancreatitis	Completed	NCT00142233	Phase 3	Magnesium
15	A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) With High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors	Recruiting	NCT02375204	Phase 3	paclitaxel;ifosfamide;cisplatin;pegylated G-CSF;G-CSF;carboplatin;etoposide phosphate
16	A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors	Recruiting	NCT03067181	Phase 3	Carboplatin;Cisplatin;Etoposide
17	A Randomized Phase III Study Comparing One Course of Adjuvant Bleomycin, Etoposide and Cisplatin (BEP) and One Course of Carboplatin AUC7 in Clinical Stage I Seminomatous Testicular Cancer	Recruiting	NCT02341989	Phase 3	Bleomycin Etoposide and Cisplatin;Carboplatin
18	A Risk-Adapted Strategy of the Use of Dose-Dense Chemotherapy in Patients With Poor-Prognosis Disseminated Non-Seminomatous Germ Cell Tumors	Active, not recruiting	NCT00104676	Phase 3	cisplatin;etoposide;ifosfamide;oxaliplatin;paclitaxel
19	A Randomized Phase III Study of Paclitaxel, Ifosfamide and Cisplatin Versus Vinblastine, Ifosfamide and Cisplatin as Second-Line Therapy for Patients With Relapsed/Resistant Germ Cell Tumors	Terminated	NCT00072215	Phase 3	cisplatin;ifosfamide;paclitaxel;vinblastine
20	Randomized, Double Blinded, Placebo-Controlled Trial of Antibacterial Prophylaxis for the Prevention of Bacterial Infections in the Post-Engraftment Phase After Allogeneic Hematopoeitic Stem Cell Transplantation	Terminated	NCT00324324	Phase 3	moxifloxacin hydrochloride;Placebo
21	Phase I/II Multicentre Trial of Salvage Chemotherapy With Gem-TIP for Relapsed Germ Cell Cancer	Unknown status	NCT00551122	Phase 1, Phase 2	cisplatin;gemcitabine hydrochloride;ifosfamide;paclitaxel
22	Tandem High-Dose Chemotherapy (HDCT) With Peripheral-Blood Stem-Cell Rescue for Patients With Metastatic Germ-Cell Tumors Failing First-Line Treatment	Unknown status	NCT01172912	Phase 2	carboplatin;cisplatin;dexamethasone;etoposide;ifosfamide
23	A Prospective Phase II Trial of Cabazitaxel in Male Patients With Chemotherapy Pre-treated Metastatic Nonseminomatous Germ-cell Tumors	Unknown status	NCT02115165	Phase 2	Cabazitaxel
24	Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer	Completed	NCT01037790	Phase 2	PD-0332991
25	Prevention of DMSO-Related Nausea and Vomiting by Prophylactic Administration of Ondansetron for Patients Receiving Autologous Cryopreserved Peripheral Blood Stem Cells	Completed	NCT00795769	Phase 2	ondansetron
26	Treatment of Recurrent or Resistant Pediatric Malignant Germ Cell Tumors With Paclitaxel, Ifosfamide and Carboplatin	Completed	NCT00467051	Phase 2	Carboplatin;Ifosfamide;Paclitaxel
27	A Phase II Study to Evaluate Low-Dose Alemtuzumab as a Glucocorticoid-Sparing Agent for Initial Systemic Treatment of Acute Graft-Versus-Host Disease	Completed	NCT00410657	Phase 2	methylprednisolone;prednisone
28	Accelerated BEP Chemotherapy for Intermediate and High Risk Metastatic Germ Cell Tumor	Completed	NCT00453232	Phase 2	cisplatin;etoposide
29	Phase II Trial of Paclitaxel, Ifosfamide, and Cisplatin in Previously Untreated Intermediate and Poor Risk Germ Cell Tumor Patients	Completed	NCT00470366	Phase 2	cisplatin;ifosfamide;paclitaxel
30	A Phase II Study of Sunitinib in Patients With Refractory or Relapsed Germ Cell Tumors	Completed	NCT00453310	Phase 2	sunitinib malate
31	Phase I/II Trial of Sequential Paclitaxel/Ifosfamide Followed by Dose-Escalated, Dose-Intensive Carboplatin, Paclitaxel and Ifosfamide With Stem Cell Support in Cisplatin-Resistant Germ Cell Tumor Patients	Completed	NCT00423852	Phase 1, Phase 2	carboplatin;ifosfamide;paclitaxel
32	Phase II Study Of Arsenic Trioxide In Patients With Refractory Germ Cell Malignancies	Completed	NCT00036842	Phase 2	arsenic trioxide
33	PHASE I/II TRIAL OF TAXOL, IFOSFAMIDE, AND CISPLATIN FOR CISPLATIN-RESISTANT GERM CELL TUMOR PATIENTS WITH FAVORABLE PROGNOSTIC FEATURES	Completed	NCT00002559	Phase 1, Phase 2	cisplatin;ifosfamide;paclitaxel
34	High Dose Carboplatin, Etoposide, Cyclophosphamide and Autologous Bone Marrow Transplantation for Relapsed and Refractory Germ Cell Cancer: A Phase II Pilot Study	Completed	NCT00002943	Phase 2	carboplatin;cyclophosphamide;etoposide
35	Myeloablative Chemotherapy With Bone Marrow Rescue For Rare Poor-Prognosis Cancers	Completed	NCT00002515	Phase 2	carboplatin;thiotepa;topotecan hydrochloride
36	Tandem High-Dose Chemotherapy With Autologous Stem Cell Rescue for Poor-Prognosis Germ Cell Cancer	Completed	NCT00002931	Phase 2	carboplatin;etoposide;ifosfamide;paclitaxel
37	PHASE II TRIAL WITH DOCETAXEL IN PATIENTS WITH RELAPSING GERM CELL CANCER	Completed	NCT00002903	Phase 2	docetaxel
38	A Phase II Study of BMS-247550 In Advanced Germ Cell Tumor Patients - THERAPEUTIC/DIAGNOSTIC PROTOCOL	Completed	NCT00070096	Phase 2	ixabepilone
39	Autologous Blood and Marrow Transplantation for Hematologic Malignancy and Selected Solid Tumors	Completed	NCT00060255	Phase 2	busulfan;carboplatin;carmustine;cyclophosphamide;etoposide;melphalan;thiotepa
40	Phase II Clinical Trial Incorporating Alemtuzumab (Campath-1H) in Combination With FK506 and Methylprednisolone for Treatment of Severe Acute Graft vs Host Disease	Completed	NCT00109993	Phase 2	methylprednisolone;tacrolimus
41	Phase II Trial of Temozolomide in Patients With Cisplatin-Refractory Germ Cell Tumors	Completed	NCT00006043	Phase 2	temozolomide
42	Combination of Interleukin 11 (Neumega) With G-CSF to Mobilize Autologous Peripheral Blood Stem Cells (PBSC)	Completed	NCT00004157	Phase 2
43	A Study of Paclitaxel, Cisplatin and Ifosfamide as Induction Therapy in the Treatment of Patients Relapsing After BEP Chemotherapy for Metastatic Germ Cell Tumors	Completed	NCT00004077	Phase 2	cisplatin;ifosfamide;paclitaxel
44	Cytokine-Based Immunotherapy Following High-Dose Chemotherapy and Autologous Stem Cell Transplantation	Completed	NCT00003408	Phase 2
45	High-Dose Thiotepa With Autologous Stem Cell Rescue in Patients With Malignancies Refractory to Conventional Chemotherapy	Completed	NCT00003173	Phase 2	thiotepa
46	PHASE I/II TRIAL OF SEQUENTIAL TAXOL/IFOSFAMIDE AND DOSEINTENSIVE CARBOPLATIN/ETOPOSIDE WITH STEM CELL SUPPORT IN CISPLATIN-RESISTANT GERM CELL TUMOR PATIENTS WITH UNFAVORABLE PROGNOSTIC FEATURES	Completed	NCT00002558	Phase 1, Phase 2	carboplatin;etoposide;ifosfamide;paclitaxel
47	INTENSIVE CHEMOTHERAPY FOR RELAPSED OR REFRACTORY GERM CELL TUMORS EMPLOYING HIGH-DOSE CARBOPLATIN, ETOPOSIDE, AND THIOTEPA WITH AUTOLOGOUS BONE MARROW RESCUE FOR PATIENTS 15 TO 60 YEARS OF AGE	Completed	NCT00002508	Phase 1, Phase 2	carboplatin;etoposide
48	A Phase I-II Safety, Tolerability And Pharmacokinetic Study Of Ravuconazole For Prophylaxis Of Invasive Fungal Infections In Patients Undergoing Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation	Completed	NCT00064311	Phase 1, Phase 2	ravuconazole
49	Vaccine Therapy With Tumor Specific Mutated Ras Peptides and IL-2 or GM-CSF for Adult Patients With Solid Tumors	Completed	NCT00019331	Phase 2	DetoxPC
50	Oral Beclomethasone Dipropionate Capsules for Treatment of Intestinal Graft-Versus-Host Disease: Compassionate Use in Patients With Contraindictions to High-Dose Immunosuppressive Therapy	Completed	NCT00010283	Phase 1, Phase 2	beclomethasone dipropionate

Search NIH Clinical Center for Testicular Germ Cell Tumor

Sources

Genetic Tests for Testicular Germ Cell Tumor

Sources

Anatomical Context for Testicular Germ Cell Tumor

Organs/tissues related to Testicular Germ Cell Tumor:

MalaCards : Testis, Pineal, Lymph Node, Bone Marrow, T Cells, Spinal Cord, Bone

Sources

Publications for Testicular Germ Cell Tumor

Articles related to Testicular Germ Cell Tumor:

(show top 50) (show all 9089)

#	Title	Authors	PMID	Year
1	Activating c-kit gene mutations in human germ cell tumors. ⁶² ⁵⁷ ⁵	Tian Q...Moskaluk CA	10362788	1999
2	Activating mutations in FGFR3 and HRAS reveal a shared genetic origin for congenital disorders and testicular tumors. ⁵⁷ ⁵	Goriely A...Wilkie AO	19855393	2009
3	Lack of Bcl10 mutations in testicular germ cell tumours and derived cell lines. ⁵⁷ ⁵	van Schothorst EM...Looijenga LH	10408400	1999
4	Lack of BCL10 mutations in germ cell tumors and B cell lymphomas. ⁵⁷ ⁵	Fakruddin JM...Murty VV	10380920	1999
5	Bcl10 is involved in t(1;14)(p22;q32) of MALT B cell lymphoma and mutated in multiple tumor types. ⁵⁷ ⁵	Willis TG...Dyer MJ	9989495	1999
6	Rare de novo germline copy-number variation in testicular cancer. ⁶² ⁵⁷	Stadler ZK...Offit K	22863192	2012
7	Variants in or near KITLG, BAK1, DMRT1, and TERT-CLPTM1L predispose to familial testicular germ cell tumour. ⁶² ⁵⁷	Kratz CP...Greene MH	21617256	2011
8	Variants near DMRT1, TERT and ATF7IP are associated with testicular germ cell cancer. ⁶² ⁵⁷	Turnbull C...UK Testicular Cancer Collaboration	20543847	2010
9	Familial testicular germ cell tumors in adults: 2010 summary of genetic risk factors and clinical phenotype. ⁶² ⁵⁷	Greene MH...Korde LA	20228134	2010
10	LINE-1 methylation is inherited in familial testicular cancer kindreds. ⁶² ⁵⁷	Mirabello L...Greene MH	20478068	2010
11	A genome-wide association study of testicular germ cell tumor. ⁶² ⁵⁷	Rapley EA...Stratton MR	19483681	2009
12	Common variation in KITLG and at 5q31.3 predisposes to testicular germ cell cancer. ⁶² ⁵⁷	Kanetsky PA...Nathanson KL	19483682	2009
13	Deletion of eIF2beta suppresses testicular cancer incidence and causes recessive lethality in agouti-yellow mice. ⁶² ⁵⁷	Heaney JD...Nadeau JH	19168544	2009
14	Increased prevalence of testicular microlithiasis in men with familial testicular cancer and their relatives. ⁶² ⁵⁷	Korde LA...Greene MH	18841155	2008
15	Testicular microlithiasis as a familial risk factor for testicular germ cell tumour. ⁶² ⁵⁷	Coffey J...Rapley EA	17971766	2007
16	Association of BCL10 germ line polymorphisms on chromosome 1p with advanced stage testicular germ cell tumor patients. ⁶² ⁵⁷	Inoue T...Habuchi T	16229939	2006
17	The Y deletion gr/gr and susceptibility to testicular germ cell tumor. ⁶² ⁵⁷	Nathanson KL...Rapley EA	16380914	2005
18	The Ter mutation in the dead end gene causes germ cell loss and testicular germ cell tumours. ⁶² ⁵⁷	Youngren KK...Matin A	15902260	2005
19	Mutations of BRAF and RAS are rare events in germ cell tumours. ⁶² ⁵⁷	Sommerer F...Tannapfel A	15386408	2005
20	A male germ cell tumor-susceptibility-determining locus, pgct1, identified on murine chromosome 13. ⁶² ⁵⁷	Muller AJ...Levine AJ	10890890	2000
21	Localization to Xq27 of a susceptibility gene for testicular germ-cell tumours. ⁶² ⁵⁷	Rapley EA...Bishop DT	10655070	2000
22	Susceptibility to testicular germ-cell tumours in a 129.MOLF-Chr 19 chromosome substitution strain. ⁶² ⁵⁷	Matin A...Nadeau JH	10508525	1999
23	Familial testicular cancer in Norway and southern Sweden. ⁶² ⁵⁷	Heimdal K...Fossa SD	8611416	1996
24	Occurrence of seminoma and dysgerminoma in father and daughter. ⁶² ⁵⁷	Yule SM...Pearson AD	8204448	1994
25	Familial testicular cancer: a report of the UK family register, estimation of risk and an HLA class 1 sib-pair analysis. ⁶² ⁵⁷	Forman D...Pike MC	1739626	1992
26	Cytogenetic and molecular analysis of human male germ cell tumors: chromosome 12 abnormalities and gene amplification. ⁶² ⁵⁷	Samaniego F...Reuter V	2177638	1990
27	Familial testicular teratoma in 2 children: familial report and review of the literature. ⁶² ⁵⁷	Shinohara M...Yokoyama M	7365898	1980
28	Father-son testicular malignancy. Does genetic anticipation occur? ⁶² ⁵⁷	Raghavan D...Fox RM	7260832	1980
29	Thanatophoric dysplasia type 2 with encephalocele during the second trimester. ⁵	Li D...Tang X	16752380	2006
30	Cytogenetic and molecular analysis of a family with three brothers afflicted with germ-cell cancer. ⁵⁷	Ottesen AM...Skakkebaek NE	15032972	2004
31	RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. ⁵	Nikiforova MN...Nikiforov YE	12727991	2003
32	The thanatophoric dysplasia type II mutation hampers complete maturation of fibroblast growth factor receptor 3 (FGFR3), which activates signal transducer and activator of transcription 1 (STAT1) from the endoplasmic reticulum. ⁵	Lievens PM...Liboi E	12624096	2003
33	Curing metastatic testicular cancer. ⁵⁷	Einhorn LH	11904381	2002
34	Coamplification of DAD-R, SOX5, and EKI1 in human testicular seminomas, with specific overexpression of DAD-R, correlates with reduced levels of apoptosis and earlier clinical manifestation. ⁵⁷	Zafarana G...Looijenga LH	11912161	2002
35	BCL10 is not a major target for frequent loss of 1p in testicular germ cell tumors. ⁵⁷	Kakinuma H...Kato T	11376806	2001
36	Point mutations and deletions of the Bcl10 gene in solid tumors and malignant lymphomas. ⁵⁷	Lee SH...Yoo NJ	10582682	1999
37	Molecular, radiologic, and histopathologic correlations in thanatophoric dysplasia. ⁵	Wilcox WR...Rimoin DL	9677066	1998
38	Somatic mutations in LKB1 are rare in sporadic colorectal and testicular tumors. ⁵⁷	Avizienyte E...Aaltonen LA	9605748	1998
39	A genetic perspective of male germ cell tumors. ⁵⁷	Murty VV...Chaganti RS	9562446	1998
40	Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. ⁵	Chesi M...Bergsagel PL	9207791	1997
41	Physical mapping of a commonly deleted region, the site of a candidate tumor suppressor gene, at 12q22 in human male germ cell tumors. ⁵⁷	Murty VV...Chaganti RS	8812492	1996
42	Familial predisposition to both male and female germ cell tumours? ⁵⁷	Huddart RA...Horwich A	8825060	1996
43	DNA pooling as a quick method for finding candidate linkages in multigenic trait analysis: an example involving susceptibility to germ cell tumors. ⁵⁷	Collin GB...Nadeau JH	8903734	1996
44	Candidate regions for a testicular cancer susceptibility gene. ⁵⁷	Leahy MG...Bodmer JG	8541838	1995
45	Thanatophoric dysplasia (types I and II) caused by distinct mutations in fibroblast growth factor receptor 3. ⁵	Tavormina PL...Wasmuth JJ	7773297	1995
46	Loss of heterozygosity identifies multiple sites of allelic deletions on chromosome 1 in human male germ cell tumors. ⁵⁷	Mathew S...Chaganti RS	7954476	1994
47	The ter primordial germ cell deficiency mutation maps near Grl-1 on mouse chromosome 18. ⁵⁷	Sakurai T...Noguchi M	8043946	1994
48	A mutation in the Ter gene causing increased susceptibility to testicular teratomas maps to mouse chromosome 18. ⁵⁷	Asada Y...Nadeau JH	8054975	1994
49	Chromosome 12 in human testicular cancer: dosage changes and their parental origin. ⁵⁷	Peltomaki P...de la Chapelle A	1458445	1992
50	Allelic deletions in the long arm of chromosome 12 identify sites of candidate tumor suppressor genes in male germ cell tumors. ⁵⁷	Murty VV...Chaganti RS	1332066	1992

Sources

Genes for Testicular Germ Cell Tumor

Genes related to Testicular Germ Cell Tumor (11 elite genes):

(show all 18)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	FGFR3	Fibroblast Growth Factor Receptor 3	Protein Coding	1208.12	Molecular basis known ⁵⁷ Pathogenic ⁵ Causative variation ⁷³ GeneCards inferred via : Disorders (show sections)	7773297 9677066 16752380 (more) 12624096 9207791 19855393
2	STK11	Serine/Threonine Kinase 11	Protein Coding	1208.12	Molecular basis known ⁵⁷ Pathogenic ⁵ Causative variation ⁷³ GeneCards inferred via : Disorders (show sections)
3	BCL10	BCL10 Immune Signaling Adaptor	Protein Coding	957.74	Molecular basis known ⁵⁷ Pathogenic ⁵ Susceptibility factor ⁵⁷ GeneCards inferred via : Publications (show sections)	9989495 10380920 10408400
4	KIT	KIT Proto-Oncogene, Receptor Tyrosine Kinase	Protein Coding	916.91	Molecular basis known ⁵⁷ Pathogenic ⁵ GeneCards inferred via : Disorders Publications (show sections)	10362788
5	HRAS	HRas Proto-Oncogene, GTPase	Protein Coding	400	Pathogenic ⁵	12727991 19855393
6	LRRC56	Leucine Rich Repeat Containing 56	Protein Coding	400	Pathogenic ⁵	12727991 19855393
7	MIR372	MicroRNA 372	RNA Gene	400	Causal ⁴⁶ Unspecified ⁴⁶	17695719 16564011 17893849
8	MIR373	MicroRNA 373	RNA Gene	400	Causal ⁴⁶ Unspecified ⁴⁶	17695719 16564011 17893849
9	STK10	Serine/Threonine Kinase 10	Protein Coding	308.12	Causative variation ⁷³ GeneCards inferred via : Disorders (show sections)
10	TGCT1	Testicular Germ Cell Tumor Susceptibility 1	Genetic Locus	58.96	MalaCards inferred ³⁹ GeneCards inferred via : Gene name (show sections)
11	KITLG	KIT Ligand	Protein Coding	32.89	Susceptibility factor ⁵⁸ GeneCards inferred via : Publications (show sections)	19483682 20228134 23640991
12	MIR133B	MicroRNA 133b	RNA Gene	50	Unspecified ⁴⁶	17893849
13	MIR140	MicroRNA 140	RNA Gene	50	Unspecified ⁴⁶	17893849
14	MIR145	MicroRNA 145	RNA Gene	50	Unspecified ⁴⁶	17893849
15	MIR200C	MicroRNA 200c	RNA Gene	50	Unspecified ⁴⁶	17893849
16	MIR302D	MicroRNA 302d	RNA Gene	50	Unspecified ⁴⁶	17893849
17	MIR367	MicroRNA 367	RNA Gene	50	Unspecified ⁴⁶	17893849
18	MIR371A	MicroRNA 371a	RNA Gene	50	Unspecified ⁴⁶	17893849

Sources

Variations for Testicular Germ Cell Tumor

ClinVar genetic disease variations for Testicular Germ Cell Tumor:

⁵

#	Gene	Name	Type	Significance	ClinVarId	dbSNP ID	Position
1	BCL10	NM_003921.5(BCL10):c.499dup (p.Ser167fs)	DUP	Pathogenic	6250	rs387906350	GRCh37: 1:85733512-85733513 GRCh38: 1:85267829-85267830
2	KIT	NM_000222.3(KIT):c.2446G>C (p.Asp816His)	SNV	Pathogenic	13863	rs121913506	GRCh37: 4:55599320-55599320 GRCh38: 4:54733154-54733154
3	HRAS, LRRC56	NM_005343.4(HRAS):c.181C>A (p.Gln61Lys)	SNV	Pathogenic	12601	rs28933406	GRCh37: 11:533875-533875 GRCh38: 11:533875-533875
4	STK11	NM_000455.5(STK11):c.812del (p.Ser271fs)	DEL	Pathogenic	1184620		GRCh37: 19:1221289-1221289 GRCh38: 19:1221290-1221290
5	FGFR3	NM_000142.5(FGFR3):c.1948A>G (p.Lys650Glu)	SNV	Pathogenic	16331	rs78311289	GRCh37: 4:1807889-1807889 GRCh38: 4:1806162-1806162
6	BCL10	NM_003921.5(BCL10):c.172C>T (p.Arg58Ter)	SNV	Pathogenic	6266	rs121918314	GRCh37: 1:85736475-85736475 GRCh38: 1:85270792-85270792
7	BCL10	NM_003921.5(BCL10):c.172C>G (p.Arg58Gly)	SNV	Pathogenic	6265	rs121918314	GRCh37: 1:85736475-85736475 GRCh38: 1:85270792-85270792

UniProtKB/Swiss-Prot genetic disease variations for Testicular Germ Cell Tumor:

⁷³

#	Symbol	AA change	Variation ID	SNP ID
1	FGFR3	p.Lys650Glu	VAR_004160	rs78311289
2	STK10	p.Lys277Glu	VAR_023827	rs757545210
3	STK11	p.Gly163Asp	VAR_033140	rs137853078

Copy number variations for Testicular Germ Cell Tumor from CNVD:

⁶ (show all 12)

#	CNVD ID	Chromosome	Start	End	Type	Gene Symbol	CNVD Disease
1	19332	1	149600000	247249719	Gain		Testicular germ cell tumor
2	42821	10	40300000	82000000	Loss		Testicular germ cell tumor
3	61421	12	1	132349534	Gain		Testicular germ cell tumor
4	89303	15	17000000	76100000	Loss		Testicular germ cell tumor
5	121721	18	46400000	76117153	Loss		Testicular germ cell tumor
6	146937	2	56300000	230700000	Loss		Testicular germ cell tumor
7	180589	4	107900000	191273063	Loss		Testicular germ cell tumor
8	206877	6	149100000	170899992	Loss		Testicular germ cell tumor
9	226157	7	55086724	55275030	Amplification	EGFR	Testicular germ cell tumor
10	245111	9	101600000	129300000	Loss		Testicular germ cell tumor
11	261703	X	24900000	29400000	Gain		Testicular germ cell tumor
12	262543	X	37500000	146900000	Gain		Testicular germ cell tumor

Sources

Expression for Testicular Germ Cell Tumor

Search GEO for disease gene expression data for Testicular Germ Cell Tumor.

Sources

Pathways for Testicular Germ Cell Tumor

Pathways related to Testicular Germ Cell Tumor according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	p70S6K Signaling ⁶⁴ Show member pathways mTOR Pathway ⁶⁴ Renin-Angiotensin Pathway ⁶⁴	12.68	STK11 KITLG KIT HRAS FGFR3
2	PI3K-Akt signaling pathway ⁷⁴ Show member pathways Focal adhesion: PI3K-Akt-mTOR-signaling pathway ⁷⁴	12.53	STK11 KITLG KIT HRAS FGFR3
3	Development EPO-induced Jak-STAT pathway ²² Show member pathways EPO receptor signaling ⁷⁴ Signaling events mediated by Stem cell factor receptor (c-Kit) ⁶¹	11.61	KITLG KIT HRAS
4	Signaling by SCF-KIT ⁶⁶ Show member pathways Regulation of KIT signaling ⁶⁶ Signaling by KIT in disease ⁶⁶ Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants ⁶⁶	11.43	KITLG KIT HRAS
5	Cell differentiation - expanded index ⁷⁴ Show member pathways Cell differentiation - index ⁷⁴	11.23	MIR302D MIR145 MIR133B
6	Head and neck squamous cell carcinoma ⁷⁴	11	STK11 HRAS FGFR3
7	miRNAs involved in DNA damage response ⁷⁴	10.75	MIR373 MIR372 MIR371A MIR145

Sources

GO Terms for Testicular Germ Cell Tumor

Cellular components related to Testicular Germ Cell Tumor according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	RISC complex	GO:0016442	9.4	MIR367 MIR302D MIR200C MIR145 MIR140 MIR133B

Biological processes related to Testicular Germ Cell Tumor according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	protein autophosphorylation	GO:0046777	10.03	STK11 STK10 KIT FGFR3
2	miRNA-mediated gene silencing	GO:0035195	9.89	MIR373 MIR372 MIR371A MIR367 MIR302D MIR200C
3	positive regulation of phospholipase C activity	GO:0010863	9.76	KIT HRAS
4	positive regulation of mast cell cytokine production	GO:0032765	9.67	BCL10 KIT
5	mast cell proliferation	GO:0070662	9.62	KIT KITLG
6	miRNA-mediated gene silencing by inhibition of translation	GO:0035278	9.58	MIR200C MIR145 MIR133B
7	positive regulation of mast cell proliferation	GO:0070668	9.56	KIT KITLG
8	melanocyte migration	GO:0097324	9.46	KITLG KIT
9	negative regulation of vascular endothelial growth factor production	GO:1904046	8.92	MIR373 MIR372 MIR302D MIR140

Molecular functions related to Testicular Germ Cell Tumor according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	mRNA 3'-UTR binding	GO:0003730	9.26	MIR200C MIR145 MIR140 MIR133B
2	mRNA base-pairing translational repressor activity	GO:1903231	9.23	MIR373 MIR372 MIR371A MIR302D MIR200C MIR145